R Vassilopoulou-Sellin1, A Sella, F H Dexeus
1Section of Endocrinology, University of Texas M.D. Anderson Cancer Center, Houston.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Interleukin-2 (IL-2) cancer therapy can cause temporary thyroid issues. Patients may develop transient thyroiditis, leading to initial hyperthyroidism followed by hypothyroidism, which often resolves.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: